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CHAPTER 1 INTRODUCTION

Background on Renal Failure
Chronic kidney disease is a general term for a variety of different disorders
affecting kidney structure and function. In the United States, the development of chronic
kidney disease is associated with old age, diabetes, hypertension, obesity, and
cardiovascular disease (Levey & Coresh, 2012). When unmanaged over long periods of
time, these conditions cause damage to and destroy the nephrons, the functional units of
the kidney. The diagnosis of chronic kidney disease is made through the presence of
either kidney damage or decreased kidney function (as measured by glomerular filtration
rate, GFR) below certain markers for a period of at least three months. When the kidney
is functioning so weakly that dialysis or transplantation is necessary for the patient to
survive (usually GFR < 15 mL/m2), the condition is labeled as “kidney failure,” also
known as “end stage renal disease” (ESRD) or “stage 5 chronic kidney disease.”
Prevalence is approximately 1,800 cases per million across the total population of the
United States, and most patients survive only 3-5 years.
For the majority of patients, ESRD is the end result of a progressive deterioration
in kidney function over a period of months or years. Although it is possible to reverse the
course of disease progression through treatment, that outcome is uncommon. The major
focus of treatment is to slow the progression of the disease and manage complications.
Most patients with ESRD undergo hemodialysis (as opposed to peritoneal dialysis) in
which a machine serves about 15% of the function of healthy kidneys, but this process
requires a time commitment of 3 days per week for 3-4 hours each time. Additionally,
most patients with ESRD have other complex medical complications such as
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cardiovascular disease and diabetes, which require a strict medication regimen to be
controlled. This places the responsibility of strict medication adherence in the hands of
the patients, in addition to their other burdensome requirements of undergoing dialysis,
and consuming reduced amounts of fluids and sodium. Finally, renal transplantation
offers better long-term outcomes than dialysis, but the supply of available kidneys is
limited.

Early Readmissions
Readmissions within 30 days after discharge from the hospital are an increasingly
important metric for evaluating the effectiveness of medical treatment. Hospital
admissions are the single most expensive episodes in healthcare, and early readmission
has been targeted as indicating a likely failure of appropriate care and/or discharge
preparation. In fact, the Affordable Care Act has instituted a policy of fining hospitals for
high 30-day readmission rates as means of incentivizing those hospitals to provide quality
care. Yet, the ESRD patient population has the highest rate of 30-day readmissions of all
patients in the Medicare/Medicaid population, averaging over 30% across all hospitals
(Medicare Payment Advisory Commission, 2007). Therefore, interventions that reduce
these early readmission rates could make an enormous difference in both improving care
for patients with ESRD while also saving money for hospitals. Yet, few interventions
have ever been developed or empirically tested via a randomized controlled trial (RCT)
to modify this outcome variable. An added benefit of reducing hospital admissions is that
it keeps patients out of danger from medical errors, which have been estimated to result
in over 210,000 deaths per year in the United States (James, 2013). The following
sections present five major behavioral risk factors (shown in Figure 1) for early
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readmissions in patients with ESRD, although as I discuss below, only social support
may be amenable to adaptive change with a brief intervention.

Cognitive
Impairment
Low Health
Literacy
Substance
Abuse

Poor
Adherence

Early
Readmission

Depression
Low Social
Support
Figure 1. Proposed Model

Risk Factors
Cognitive Impairment
Cognitive impairment, an umbrella term that includes both chronic and acute
deficits in cognitive functioning, is increasingly recognized as a primary psychosocial
risk factor for excessive healthcare utilization and hospital admissions. In general, the
most common cause of cognitive impairment is the normal aging process. Patients with
ESRD are particularly at risk due to their high comorbidity with medical conditions that
affect the central nervous system, such as hypertension, diabetes, smoking, and

4
atherosclerosis (Ketterer, Soman, & Mossallam, 2014). Furthermore, patients with ESRD
are also at risk for delirium resulting from various causes, such as encephalopathy due to
the failing kidney (increased uremia, hyperkalemia, hyperphosphatemia, and acidosis)
and side effects from medications. Delirium, which is characterized by confusion,
disorientation, and attention problems that fluctuate over time, has been shown to have
particularly negative consequences for both patients and support members (O'Malley,
Leonard, Meagher, & O'Keeffe, 2008). Cognitive impairment has been found to be
related to poor self-care adherence (Cameron et al., 2010) and to prospectively predict
readmission and mortality (Dodson, Truong, Towle, Kerins, & Chaudhry, 2013; Watson
et al., 2011). Cognitive impairment also may be the principle factor for early readmission
in at least some populations, such as those with congestive heart failure (Ketterer, Draus,
McCord, Mossallam, & Hudson, 2014). Preliminary analyses have replicated these
findings in the very hospital where I conducted this study. A prospective study assessed
patients with ESRD for a variety of different risk factors when they were initially
admitted to the hospital, and found that cognitive impairment, substance abuse, and low
health literacy at baseline predicted 30-day readmissions (Ketterer, Soman, et al., 2014).
Additionally, an unpublished retrospective review of medical records of patients with
ESRD that I conducted showed that the presence of one or more positives on a "cognitive
composite" index (history of delirium, positive head CT or MRI, history of seizures,
history of hypoxia) was significantly related to the presence of a 30-day readmission
within the past year (Jasinski, Lumley, Soman, Yee, & Ketterer, in press). Unfortunately,
cognitive impairment is rarely identified in healthcare settings, and usually remains
unattended to in this population (Tamura & Yaffe, 2011). Therefore, simply raising
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awareness about cognitive impairment in patients with ESRD might help their physicians,
other medical staff, and support people plan for appropriate home care after discharge.
Depression
Patients with ESRD face unique psychological stressors due to their extreme
dependence on technology for survival as well as the time-consuming demands on their
health behaviors (Christensen & Ehlers, 2002). Living with ESRD entails a variety of
chronic, recurrent stressors, significant change in lifestyle, disruption of familial roles and
social identity, and threatened personal control, mainly due to the requirements for
dialysis. Psychological distress and disorder represent a significant detriment to ESRD
patient quality of life. Estimates of the prevalence of depression in this population are
that 20-25% of ESRD patients meet diagnostic criteria for major depression (Kimmel,
Cukor, Cohen, & Peterson, 2007). The loss of control that comes with ESRD has been
identified as an important contributing factor to this depression. Illness intrusiveness,
which is very high due to the requirements of hemodialysis, has also been shown to be a
contributor to depression (Christensen & Ehlers, 2002). Additionally, depression may be
under recognized and under treated in this population, and even when intervention
attempts are made, treatment has often been unsuccessful (Fallon, 2011).
Substance Abuse
Cocaine and other substances have been identified as causes and exacerbating
factors of renal failure (Norris et al., 2001). Accordingly, substance abuse is very
prevalent in patients with ESRD, in spite of the fact that it accelerates the deterioration of
their health (Kimmel, Thamer, Richard, & Ray, 1998). In general, substance abuse has
been linked with greater health care utilization, especially in populations with low socio-
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economic status (Kushel, Vittinghoff, & Haas, 2001). In a study conducted at Henry Ford
Hospital, where I conducted this dissertation, substance abuse prospectively predicted
early readmissions in patients with chronic kidney disease. Finally, although the impact
of substance abuse on interventions with inpatients is largely unknown, it could be an
important moderating variable. For example, substance abuse could potentially be a
barrier to the success of the intervention.
Health Literacy
Another psychosocial factor attracting much attention is “health literacy,” defined
as the ability of patients to understand the language used to educate them regarding their
medical conditions as well as the medical treatments used to manage their health (Kindig,
Panzer, & Nielsen-Bohlman, 2004). Low health literacy has been associated with various
adverse outcomes including an increase in hospital admission/readmission rates (Baker,
Parker, Williams, & Clark, 1998; Mitchell, Sadikova, Jack, & Paasche-Orlow, 2012). In
the case of patients with ESRD, increased mortality has also been found to be associated
with low health literacy (Cavanaugh et al., 2010). However, the mechanism by which
health literacy impacts outcomes is unclear, and the possibility of a third factor such as
socioeconomic status that confounds or mediates any observed association must be
considered and controlled or eliminated. For example, research has shown that the
improvements assumed to occur with greater health literacy—better disease knowledge,
healthier behaviors, more use of preventive care, and compliance—could not account for
a relationship between health literacy and use of hospital services (Cho, Lee, Arozullah,
& Crittenden, 2008). Most important of all, there have been no randomized controlled
trials providing evidence that health literacy is a causal variable (Ketterer, Mahr, &
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Goldberg, 2000). In summary, education-focused and behaviorally-based interventions
focus on helping patients by improving their health literacy, which is certainly an
important variable. Some of these interventions have even included family and friends to
a certain extent.
Social Support
Although there are many variables that are risk factors for poor outcomes in
patients with ESRD, social support serves as a protective factor. Additionally, whereas
there is little or no evidence that we can use brief bedside interventions to attenuate the
above risk factors and improve outcomes in patients with ESRD, there is evidence that
psychosocial interventions involving family members can reduce patient and caregiver
burden, and improve mood in these patients with various chronic illnesses (Martire,
Lustig, Schulz, Miller, & Helgeson, 2004). In general, health literacy and individual
differences in health behavior are often implicated as potential mediators of the
association between social support and physical health (S. E. Cohen & Syme, 1985).
Therefore, an increase in social support could help compensate for the presence of these
risk factors. Also, a supportive family environment has been identified as a particularly
important protective factor for chronically ill individuals in terms of self-management of
their health behaviors such as diet (Gallant, 2003). As is the case with other clinical
populations, various indices of the quantity and perceived quality of social support have
been associated with more favorable psychological adjustment and reduced risk of
mortality among patients with chronic kidney disease (Christensen, Wiebe, Smith, &
Turner, 1994; S. D. Cohen et al., 2007). Perceived social support is also associated with
less depressive and suicidal thoughts among patients with ESRD (Soykan, Arapaslan, &
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Kumbasar, 2003).

Potential Mediator: Medication and Dialysis Adherence
Patients with ESRD have a reputation for being “difficult” to work with, because
their medical cases are usually complex, and adherence is commonly lower than among
patients with other diseases (Christensen & Ehlers, 2002). One explanation for low
adherence involves the high burden experienced by patients with ESRD. For example,
patients on hemodialysis are required to commit to three dialysis sessions per week,
which take a few hours each time. In addition, patients are prescribed dietary restrictions
that significantly limit their food options. Therefore, it is unsurprising that many patients
say that they feel “over-doctored” and overwhelmed by the amount of self-care that is
necessary for them to survive (Levy, Cohen, & Tessier, 2006). Studies examining the
prevalence of nonadherence among renal dialysis patients have typically observed that
between 30% and 60% of patients do not adhere to diet, fluid-intake, and medication
regimens (Bame, Petersen, & Wray, 1993). These studies have relied almost entirely on
cross-sectional, self-report assessment of patient characteristics and adherence outcomes.
Adherence to health behaviors such as taking medications as prescribed and
attending dialysis sessions has been proposed as the primary mechanism by which the
various risk factors described above lead to early readmissions, and represents a mediator
by which risk factors translate into poor health outcomes. Patients with ESRD have a
unique set of clinical, socio-demographic, and psychosocial factors that have been
examined as potential correlates or determinants of adherence behavior, including
cognitive impairment, family support, depression, health beliefs, and health literacy
(Cameron et al., 2010; Karamanidou, Clatworthy, Weinman, & Horne, 2008). Simply,

9
patients who are too forgetful or confused to take their medications regularly experience
negative health effects (including mortality) as a result, and, therefore, require
hospitalization in order to recover (Kimmel, Peterson, et al., 1998; Kimmel et al., 2000;
Leggat et al., 1998). For example, cognitive impairment, depression, substance abuse,
and younger age have all been linked to worse hemodialysis adherence (Mellon, Regan,
& Curtis, 2013).

Social Support and Adherence
Limited research is available regarding the relationship between social support
and adherence among patients with ESRD. For example, there is a large body of research
in other populations that suggests that many different aspects of social support
(emotional, practical, etc.) are important correlates of regimen adherence (DiMatteo,
2004). Christensen et al. (1992) examined the effects of family social support and illnessrelated stress on hemodialysis patient adherence. Patients who reported a more supportive
family environment, characterized by greater cohesion and expressiveness among family
members and less intrafamilial conflict, exhibited significantly more favorable adherence
to fluid-intake restrictions than did patients reporting less family support. Likewise, being
married has been linked to increased adherence to hemodialysis (Alkatheri et al., 2014).
A major limitation of the research is that family and social support interventions
have not been tested within patients with ESRD to determine how they might impact
medication adherence or the specific health outcome of early readmissions after hospital
discharge. On the other hand, this lack of data presents an opportunity to test the ability
of health care professionals to mobilize social support, which may be more amenable to
change than the other risk factors of early readmission, such as cognitive impairment,
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health literacy, depression, and substance abuse. Additionally, across the literature, the
impact of social support has been assessed using a variety of different measures, which
means that there is robust evidence that shows social support to be a protective factor in
patients with ESRD. But, the downside is that social support is a broadly defined
construct, so it is difficult to determine which specific factors might carry the most
impact in a potential intervention.

Interventions for adherence
Given the prevalence of ESRD and clinical importance of adherence among
patients diagnosed with this condition, the design and evaluation of interventions to
improve adherence is critically important. The ESRD population has been identified as
ripe for specific interventions designed to mobilize social support (Chisholm‐Burns,
Spivey, & Wilks, 2010; Cukor, Rosenthal, Jindal, Brown, & Kimmel, 2009). However,
most interventions in this population have not attempted to utilize social support, and no
interventions have been tested for their ability to reduce early readmissions in patients
with ESRD. Therefore, in this section I will review interventions that have aimed to
improve my primary hypothesized mediator variables, medication and dialysis adherence.
Most ESRD adherence intervention studies (at least 10 in total) have used
behaviorally-oriented techniques. There is evidence to suggest that a range of behavioral
strategies (e.g., self-monitoring, behavioral contracting, and positive reinforcement) are
associated with small to medium effect size improvements in adherence among
hemodialysis patients (Matteson & Russell, 2010). However, many of these studies are
limited to single-subject or very small sample designs, and conducted over multiple
sessions with outpatients. For example, a pre-post design study showed that a 3-month
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motivational interviewing intervention improved dialysis attendance as well as
biomarkers of kidney health at follow-up (Russell et al., 2010). Also, Binik et al. (1993)
reported that a brief, enhanced-education intervention focusing on increasing patient
knowledge about the basic pathophysiology of kidney disease, and options for treatment
strategies led to a delay in the need to initiate renal dialysis compared with a standardeducation control group. Cukor et al. (2013) conducted a large cognitive behavioral
therapy (CBT) intervention that occurred while patients were seated at their hemodialysis
appointments, and found that the CBT group demonstrated significantly higher adherence
to fluid intake restrictions (among other psychosocial improvements), but no
improvement with adherence to prescription medications, when compared to a wait-list
control group. These interventions, although somewhat encouraging, would not be as
feasible with inpatients, particularly those with cognitive impairment, who, in
comparison, are much sicker than those in outpatient dialysis units.

Putting it all together: Considerations for intervention
In terms of the focus of the intervention, there are several risk factors that have
been previously targeted for intervention in this population, including depression and
substance abuse. However, these variables have already been investigated, and usually
take many recurring sessions of treatment before any improvement is noticeable.
Therefore, this study, although not ignoring these variables, placed an emphasis on
domains that have not yet been tested, such as compensating for cognitive impairment. A
key aspect of this study is that we targeted patients who had already demonstrated the
lack of capacity for proper adherence, and are most at risk for poor adherence and
readmissions, in order to work with those who need the most help and use the most
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resources. These patients likely would not respond very well to the CBT interventions
that have already been tested. Of the five risk factors for poor adherence and early
readmissions mentioned above, social support is the one with the most potential to be
modified by a brief family consultation. Thus, mobilizing family support to help patients
adhere to their medication schedule is something that can potentially be achieved in one
brief psychoeducation session. In addition, family involvement could help benefit
patients with low health literacy as well.
There are several other considerations for the process of the intervention. First,
the consultation-liaison literature has demonstrated that bedside psychiatric consultations
can maximize efficiency as well as reducing patient burden (Griffith & Gaby, 2005).
Accordingly, we kept the intervention brief to minimize the burden on patients and their
support people, as well as reducing the potential cost of this intervention in a real-world
setting. Importantly, pragmatic research methods like this would allow this study to
achieve the goal of being more on the effectiveness side of the spectrum as opposed to
efficacy. Second, health literacy issues will need to be considered as a common concern
in this population. Interventions to improve health literacy have included advocating the
importance of use language that is easy to understand, promote empowerment in patients,
and mobilize social support (Gazmararian, Jacobson, Pan, Schmotzer, & Kripalani,
2010). However, the goal of the intervention is to compensate for low health literacy,
rather than to try to change health literacy. Therefore, as part of this intervention, it will
be important to use words that patients can understand and do not provoke defensive
responses, such as discussing “forgetfulness” instead of “cognitive impairment” or
“dementia.” We also utilized motivational interviewing techniques as necessary when
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patients were resistant or skeptical of the intervention (Levy et al., 2006; Miller &
Rollnick, 2012). Furthermore, although attending to medications and dialysis will be the
main focus of the intervention, it would be efficient to mention the importance of
managing any evident depression symptoms and abstaining from alcohol and other
substances.
There is some debate regarding the optimal way to quantify the outcomes of this
study. We used 30-day inpatient readmissions as a dichotomous variable as our main
outcome because that is the statistic currently attracting attention due to its use by CMS
to determine fines for high readmission rates. This metric is also easy to understand and
face valid for explaining to patients and other people who are not versed in the
complexities of hospital procedures. However, return visits for observation or to the
emergency department are also clinically relevant and important metrics for patient
health and quality of life as well as evaluating hospital performance and funding.
Therefore, we created a second variable to encompass whether or not a patient had any
type of return visit. Finally, readmission status at three months was also assessed as a
secondary outcome variable.

Summary and Goals of Study
A variety of risk factors cause poor medication and dialysis adherence in patients
with ESRD, but increased family support may be able to counteract these limitations and
improve adherence. The main goal of this study was to use a randomized clinical trial to
test the efficacy / effectiveness of a brief family meeting consultation aimed at improving
the health behaviors of patients with ESRD to prevent early readmissions to the hospital.
We will also analyze observation status and emergency department visits as outcomes
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because although they are not yet being targeted by the Affordable Care Act, they
represent clinically relevant outcomes. As secondary goals, we investigated the mediators
of this process by monitoring changes in social support, medication and dialysis
adherence, and mood and their relation to the outcome variables. Baseline cognitive
impairment and history of substance abuse were examined as moderators.
Finally, I sought to replicate our preliminary study linking cognitive impairment
with 30-day readmissions because these findings are relatively novel in the literature and
may have important implications for potential mechanisms of this intervention. This was
done by examining if baseline cognitive impairment indicators from the chart review
predicted readmissions for the sample as a whole, ignoring experimental condition
assignment.

Hypotheses
I hypothesized that:
(1) The intervention group would have significantly fewer 30-day (and 3 month)
readmissions and hospital visits than the medical treatment-as-usual control group.
(2) Social support and adherence would increase more in the intervention group than the
control group, and would mediate the relationship between condition assignment and
outcomes.
(3) Baseline cognitive impairment and history of substance abuse were run as exploratory
moderator analyses, so no hypotheses were made.
(4) Measures of cognitive impairment from the chart review and baseline assessment
would positively predict 30-day readmissions.
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CHAPTER 2 METHODS

Participants
Participants were 120 adults who had end stage renal disease and were
hospitalized at Henry Ford Hospital in Detroit, Michigan. Inclusion criteria were a
current admission to the Nephrology unit and willingness to contact a family member or
friend who was expected to be available and responsive to the consultant, if the patient
was randomized into the experimental condition. To maximize generalizability of this
sample to the larger population of patients with ESRD, there were few exclusion criteria:
delirium, unavailability/discharge before recruitment and informed consent, and inability
to speak English. Patients were paid $40 for their participation in the study ($20 at
baseline and $20 at follow up).

Procedure
Risk Factor Screening Chart Review
A chart review was used as a screening measure to identify the patients admitted
to the Nephrology unit who are most at risk for readmission. A pilot study (Jasinski et al.,
in press) found that age and cognitive impairment variables (such as history of delirium
and positive brain imaging results) can be used as screening variables to identify which
patients in the nephrology unit are at higher risk for being readmitted to the hospital
within 30 days. The experimenter tried to recruit all patients with ESRD, but, given time
constraints, when multiple patients were available for recruitment simultaneously,
priority was given to patients who screened positive for one or more risk factors for early
readmission.
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Recruitment and Randomization
This trial was registered at clinicaltrials.gov (NCT02504021) prior to recruitment,
which ran from August 2015 to April 2016, with outcome assessment completed in May
2016. The randomization scheme was created before recruitment began by an
independent research assistant. Randomization was conducted using randomization.com;
it was stratified by patient gender (male or female), conducted in randomized blocks of 6
or 8, and the assignments were placed in sealed envelopes. Figure 1 presents the flow of
patients through the trial. All recruitment and intervention procedures were conducted by
a trained, male, clinical psychology doctoral student, who was supervised by a doctoral
psychologist with extensive experience in health psychology interventions. Patients were
approached at bedside, and those who met study criteria provided written, informed
consent to the IRB-approved protocol. Patients then completed an initial assessment
using several questionnaires, some of which informed the subsequent family consultation
(see below). Questionnaire items were read aloud by the researcher to assure the patient’s
understanding, given concerns about literacy in this population. Following the
assessment, the researcher unsealed the envelope to determine the assigned condition;
patients and the researcher were blind to condition assignment prior to this.
As part of the screening process at the initial meeting, we carefully discussed with
the patients whether or not they had a reliable family member or friend (ideally living in
the same household) who might be willing to come meet with us at the hospital. Those
participants who potentially met study criteria and remained interested were invited to
review the study procedures, provide written, informed consent, and complete baseline
questionnaires. Then, they were randomized into the experimental or control condition.
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Finally, the researcher verbally assessed stress level and stage of change regarding
openness to having someone help with their medications (Miller & Rollnick, 2012). This
information was used in planning for the family consult, which was designed to remain
flexible as would be consistent with a motivational interviewing approach.
For patients randomized into the consultation condition, the researcher spoke with
them about selecting a family member or friend to come to meet them in the hospital and
agreeing to participate in the study. We also scheduled a time for the appointment and
confirmed with the support people that they could attend. However, in-person family
meetings were often not feasible, so to maximize participation and feasibility, some
family consultations occurred by telephone. In such cases the consultation was conducted
with the family member over the phone, and patients were briefed about the content of
the discussion. Then, the family meeting was conducted as soon as possible, ideally
before the patient was discharged. Support people were provided with information sheets
when meetings were in-person, and provided verbal consent for consults that were done
over the phone. Family meetings were conducted in-person when the family was already
present at the hospital. Method of contact was recorded for analysis as a potential
moderator.
At follow-up, a chart review was conducted by a member of the research team
one month after the discharge of each participant to determine if he or she was readmitted
to the hospital within that time frame (which represents the window where hospitals are
financially penalized).

Other variables such as observation status admissions and

emergency department visits were also recorded. All codes for readmissions were
independently confirmed by a senior hospital psychologist who was blinded to patient
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randomization. We reviewed the charts again at three months to assess longer-term
readmission status as a measure of health. There was little data available about
readmissions to hospitals outside of the Henry Ford, so it was not included. Patients in
both the consultation and control conditions were called to administer the follow-up
measures after 1 month, and if patients could not be reached via phone after three
attempts, were mailed with return envelopes.
Family Consultation Condition
The family consultation consisted of one relatively brief session. To maintain trial
integrity and avoiding confounding by the medical team, the doctoral student / family
consultant worked independently from the rest of the health care team on the unit, leaving
them essentially blind to patient consultation condition.
The consultation had several components. The consultant:
1) introduced himself and informed the patient and family member that the health care
team is working to improve post-discharge care by communicating better with the
patient’s support people;
2) built rapport by providing empathy regarding the burden of managing ESRD;
3) reviewed patient and family understanding of events that caused the hospital
admission;
4) educated patient and family about of the level of cognitive impairment that the patient
was experiencing by discussing the results of the initial cognitive assessment;
5) discussed ways for the support person to assist the patient with his or her medication
adherence, even when the patient displayed no overt signs of cognitive impairment;
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6) tailored the consultation to each patient by including other risk factor data from the
initial assessment (i.e., health literacy, social support, and adherence) as indicated;
and
7) used motivational interviewing techniques, as indicated, such as asking permission to
make recommendations, and reflecting ambivalence over treatment adherence.
The detailed protocol is included in Appendix A.
Control Condition
After the initial patient assessment, control participants engaged only in their
medical treatment as usual (TAU). No family consultation was conducted.
Screening and Predictor Measures (Baseline only):
Demographic and Medical Status Variables
A researcher conducted the review of the following variables: age, gender, race,
history of substance abuse, history of delirium, history of seizures, history of hypoxia,
history of psychiatric history, presence of psychiatric medications, number of past year
hospital readmissions, length of time on dialysis, comorbid health conditions, serum
creatinine, BUN level, and phosphorous.
Cognitive impairment
Cognitive impairment and education was assessed with The Montreal Cognitive
Assessment (MoCA; (Nasreddine et al., 2005)), which is a brief (~10 minute), easily
administered and scored screening instrument to detect cognitive impairment among
patients in medical settings. It was designed to provide physicians a method of
assessment for dementia that can be done quickly and requires minimal training to
administer and score. The measure assesses: a) executive function (after being given a
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full sheet of paper with a large circle drawn on it, patients are instructed, “Draw me a
clock, put all the numbers on it and make it say 10:15”); b) naming (“What are these
three animals?”); c) immediate memory (“Repeat these three numbers: 2, 1, 8, 5, 4”); d)
language (world fluency and sentence repeat); e) abstraction (similes); f) short-term
memory (after a 5 minute delay during which the patient was distracted: “What were
those five words I read to you earlier you?”); and g) orientation (“Name the current date
& building we are in.”). Finally, 1 point is added to the score of patients who have no
education beyond a high school level.
Health Literacy
The Rapid Estimate of Health Literacy in Medicine (REALM) (Davis et al., 1993)
is a brief screening instrument designed for use in medical settings to assess patients’
reading level. The instrument consists of having patients read two lists of 8 and 7 words
aloud and usually takes less than 2 minutes. Patients are scored one point for each word
that they pronounce correctly. Scores are interpreted in terms of grade equivalent reading
level, with a perfect score corresponding to an above 9th grade level reading capability.
Outcome Measures:
Outcome Measure: Early Readmissions
The outcomes for this trial were obtained from the electronic medical record of
each patient. The primary outcome variable for this study was early (30-Day) hospital
readmissions. We operationalized this variable in two ways. First, we calculated the
percentage of study patients who had another inpatient readmission within 30 days of
discharge. This metric is easy to understand and directly relates to the financial penalties
levied by the Affordable Care Act, but may be lacking in nuance and fail to capture the
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range of negative events. Thus, we also calculated the percentage of patients who had any
unplanned return visit to the hospital (inpatient readmissions, observation unit visits, and
emergency department visits) within 30 days of discharge. We believe that the
observation and emergency department visits represent clinically relevant outcomes and
therefore should also be studied in an effort to prevent them. All outcome data were
initially retrieved by the consultant, and then independently retrieved by a senior staff
member who was blinded to experimental condition. Complete agreement between the
two coders was over 98%; the few differences were resolved by discussion and
consensus.
Social Support
At both baseline and follow-up, perceived social support was assessed using items
from the Modified Scale of Social Support-5 (MSSS), which is an abbreviated version of
the full-length MSSS (Sherbourne & Stewart, 1991). This self-report questionnaire takes
about 2-3 minutes to complete and has a Cronbach’s alpha of .87 (Sherbourne & Stewart,
1991). Items are rated on a scale of 1 (None of the time) to 5 (All of the time). Higher
scores

indicate

greater

perceived

social

support.

Item

domains

include

emotional/informational support, tangible support, affectionate support, and positive
social interaction. This questionnaire has been used in important studies linking social
support with adherence in patients with ESRD (Chisholm‐Burns et al., 2010). Internal
consistency in this sample was α = .77 at baseline and α = .73 at 1-month follow up.
Medication Adherence
At both baseline and follow-up, adherence to medication was assessed using a
modified version of the Immunosuppressant Therapy Adherence Scale (ITAS)

22
(Chisholm, Lance, Williamson, & Mulloy, 2005). The only change to this scale was to
change the language from immunosuppressant medication to include all medications.
Several studies have provided evidence for the validity of this measure to assess
adherence in organ transplant populations and has specifically been used in patients with
ESRD. The 4 items refer to behaviors over the past month: “How often did you forget to
take your medications?; How often were you careless about taking your medications?;
How often did you stop taking your medications because you felt worse?; How often did
you miss taking your medication for any reason?” The four response options for each
item are 0% of the time, 1-20%, 21-50%, and over 50% of the time. Internal consistency
was found to be Cronbach’s α = .81 during initial development. (Chisholm et al., 2005).
A fifth item, “How often did you miss your planned dialysis sessions?,” was also added
for this study. Including this item, internal consistency was α = .78 in this sample at
baseline, and α = .74 at 1-month follow up.
Depression
At both baseline and follow-up, depression was assessed using the Patient Health
Questionnaire-8 (PHQ-8) (Kroenke, Spitzer, & Williams, 2001). This measure is one of
the most widely used assessment tools in healthcare settings. It consists of 8 items based
on the diagnostic criteria for major depressive disorder, with response options ranging
from 0 (Not at all) to 4 (Almost every day) asking about the patients’ experiences over
the past two weeks. Higher scores indicate greater depression. Cronbach’s alpha for this
measure was .89 during initial validation, and in this sample was .81 at baseline and .82
at 1-month follow up.
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Anxiety
At both baseline and follow up, anxiety was assessed using the Generalized
Anxiety Disorder 7-Item Scale (GAD-7) (Spitzer, Kroenke, Williams, & Löwe, 2006).
The measure is one of the most widely used assessment tools for anxiety. Items are rated
from 0 (Not at all) to 3 (Nearly every day); higher scores indicate greater anxiety.
Cronbach’s alpha for this measure during initial validation was .89, and in this sample
was .84 at baseline and .91 at 1-month follow up.
Researcher Ratings Post-Consultation
A rating scale was developed for this project to characterize and describe the
family meetings. The first section of the scale contained 9 items ranging from 0 (not at
all) to 4 (a lot) that allowed the consultant to subjectively rate the interactions with the
family and perceived success of the meeting. Example items referring to the perceived
reactions of the support people were “developed greater awareness of barriers to
adherence” and “seemed to appreciate the consult.”

Statistical Analysis
The trial was powered to detect a difference between consultation and control
conditions of 20%, which we estimated to be a clinically meaningful effect. To obtain
power of .80 using a chi-square test and 1-tailed (directional) alpha of .05 indicated that
at least 55 patients per condition were needed (that is, at least 110 patients). Recruitment
also targeted and achieved equal numbers of men and women. Initial analyses examined
the success of randomization by comparing background demographic, medical, and
psychosocial measures between the consultation and TAU control conditions.
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Primary, intent-to-treat analyses of the effects of the consultation versus control
condition on the presence / absence of readmission were conducted with 2x2 chi square
tests. Treatment effects on continuous variables (i.e., social support, anxiety, depression,
adherence) variables were tested using repeated measures ANOVA comparing baseline to
1-month follow up scores. As detailed below, three patients never received their
randomly assigned consultation, so in addition to intent-to-treat analyses of all
randomized patients, we also ran “per protocol” analyses, comparing those patients who
received the consultation to all controls.
For statistical tests with hypothesized direction (consultation condition vs. TAU
in readmission and return hospital visits), we used 1-tailed tests with an alpha of .05; all
other tests were 2-tailed with alpha at .05.
For effect sizes, I calculated number needed to treat (NNT); that is, the number of
patients who would need the consultation to prevent a negative outcome (an early
readmission or unplanned hospital visit), compared to TAU. I also calculated effect sizes
for all 1-month self-report outcomes. The between-condition effect size for secondary
outcome variables were calculated at follow-up using the following equation: [(Family
Consultation follow-up M – baseline M) – (TAU follow-up M – baseline M)] / SD of the
pooled baseline scores. Effect sizes of 0.2 SD, 0.5 SD, and 0.8 SD are considered small,
medium, and large, respectively.
A few analyses were run in an exploratory fashion: regressions to test cognitive
impairment as a moderator, and the predictive value of therapist post-session ratings.
Also I ran t-tests and Chi-squares to examine if any of the baseline variables predicted
30-day readmissions. Finally, I ran some supplementary medical cost offset analyses to
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estimate the amount of money potentially saved by this intervention, as a function of the
difference in days of inpatient stays resulting from readmissions between the two groups.
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CHAPTER 3 RESULTS
Sample Descriptives
As shown in Figure 1, we screened 171 patients and randomized 120 of them. I
approached 51 other patients about participation, and 15 did not meet study criteria, 31
declined to participate, and 5 were excluded for miscellaneous reasons. As shown in
Table 1, the randomized sample was half male and half female, had a mean age of 57.5
years (SD = 14.4; range = 24-88), was predominantly African American (85.8%), and
less than half (42.5%) had education beyond high school. In addition to their ESRD
diagnosis, most patients had many medical comorbidities, some of which are shown in
Table 1. The two conditions were compared on these background variables to determine
the success of randomization; none of the variables differed significantly between
conditions. Note: Based on statistics available from this hospital, the 30-day readmission
rate for patients with ESRD is around 25%, which is slightly below the national average.
The 30-day readmission rate in this sample was 32% in the TAU control group, therefore
it is possible that this sample was slightly more at-risk than the usual hospital population.
The consultation was conducted as planned for 57 of the 60 patients randomized
to the family consultation condition. Family consultations did not occur for 3 patients, for
whom the interviewer was unable to reach any support person, even after three attempted
telephone calls. The 57 consultations were relatively brief, averaging about 8 min (SD =
5.0 min, range: 2 to 30 min); 23 consultations (40%) were conducted with the family at
bedside, and the rest were conducted over the telephone. Consultations involved a variety
of different support people: 17 (30%) spouses, 12 (21%) children, 10 (16%) parents, 6
(11%) siblings, 6 (11%) multiple people, 6 (11%) non-relatives.
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Figure 2. CONSORT Flowchart

Enrollment

Assessed for eligibility
(n = 171)
Excluded (n = 51)
Not meeting inclusion criteria
(n = 15)
Declined to participate
(n = 31)
Other reasons (n = 5)

Analysis

Follow up

Allocation

Randomized
(n = 120)

Allocated to intervention
(n = 60)

Allocated to control
group (n = 60)

Received allocated intervention (n
= 57)

Received allocated
condition (n = 60)

Did not receive allocated
intervention (n = 3; could not
reach family member for consult)

Did not receive allocated
condition (n = 0)

Lost to follow up
(n = 0)

Lost to follow up
(n = 0)

Discontinued
intervention (n = 0)

Discontinued
intervention (n = 0)

Analyzed (n = 60) for
Intent-to-treat
analyses

Analyzed (n = 60)

(n = 57) 3 patients were
excluded from per-protocol
analyses

Excluded from analysis
(n = 0)
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Randomization Check
Table 1 presents the sample data on 30 baseline variables that were compared
across treatment groups to determine the success of randomization. At a confidence level
of p < .05, there were no significant differences between the two groups, and therefore we
deemed the randomization to be successful.
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Table 1. Characteristics of the full sample and family consultation and
control conditions separately
Variable
Total
Consultation Control
t or
N = 120
n = 60 (50%) n = 60 (50%) χ2
Demographics
Age (M, SD)
57.5 (14.4)
58.0 (13.9)
56.97 (15.1)
-1.03
Gender (Male)
60 (50.0%)
30 (50.0%)
30 (50.0%)
0.00
Gender (Female)
60 (50.0%)
30 (50.0%)
30 (50.0%)
0.00
Race (Black)
103 (85.8%) 51 (83.0%)
52 (86.7%)
0.08
Race (White)
17 (14.2%)
9 (15.0%)
8 (13.3%)
Grade > 12th
51 (42.5%)
24 (40.0%)
27 (45.0%)
0.31
Medical risk factors
Congestive heart failure
58 (48.3%)
28 (46.7%)
30 (50.0%)
0.13
Smoking
71 (59.2%)
35 (58.4%)
36 (60.0%)
0.34
Diabetes
74 (61.7%)
42 (70.0%)
32 (53.3%)
3.53
Hypertension
118 (98.3%) 59 (99.2%)
59 (99.2%)
0.00
COPD
22 (18.3%)
10 (16.7%)
12 (20.0%)
0.22
Blood Urea Nitrogen (M, SD) 40.72 (22.65) 38.42 (18.67) 43.02 (26.00) 1.11
Serum Creatinine (M, SD)
7.35 (3.65)
6.97 (3.34)
7.74 (3.93)
1.16
Phosphorous (M, SD)
4.37 (1.69)
4.12 (1.45)
4.63 (1.88)
1.68
Charlson Comorbidity(M, SD) 7.47 (3.14)
7.60 (3.02)
7.33 (3.27)
0.46
Behavioral risk factors
Psychiatric diagnosis
35 (29.2%)
17 (28.3%)
18 (30.0%)
0.04
Psychiatric medication
30 (25.0%)
14 (23.3%)
16 (26.7%)
018
Substance use history
31 (25.8%)
11 (18.3%)
20 (33.4%)
3.52
Positive tox screen
11 (9.2%)
4 (6.6%)
7 (11.6%)
0.90
Past Year Admissions (M, SD) 2.94 (3.06)
2.75 (2.32)
3.13 (3.67)
0.68
Cognitive risk factors
Delirium
37 (30.8%)
17 (28.3%)
20 (33.3%)
0.35
Positive head imaging
61 (50.8%)
29 (48.3%)
32 (53.3%)
0.30
History of seizures
14 (11.7%)
6 (10.0%)
8 (13.3%)
0.32
History of hypoxia
19 (15.8%)
6 (10.0%)
13 (21.6%)
3.06
Dementia
5 (4.2%)
2 (3.3%)
3 (5.0%)
0.21
Stroke history
10 (8.3%)
4 (6.7%)
6 (10.0%)
0.44
Cognitive impairment
20.5 (4.50)
20.5 (4.79)
20.4 (4.22)
-0.05
Baseline Assessment
REALM-R (M, SD)
5.22 (2.62)
5.29 (2.50)
5.15 (2.75)
-0.29
REALM-SF (M, SD)
5.46 (2.11)
5.51 (2.02)
5.42 (2.22)
-0.23
Social Support (M, SD)
2.93 (1.00)
2.92 (0.95)
2.94 (1.06)
0.11
Adherence (M, SD)
2.38 (0.60)
2.38 (0.57)
2.38 (0.64)
-0.03
Depression (M, SD)
6.78 (4.59)
6.88 (4.26)
6.69 (4.94)
-0.22
Anxiety (M, SD)
5.29 (4.56)
5.22 (4.13)
5.17 (5.00)
-0.39
Note. Consultation and control conditions did not differ significantly (p < .05) on
any of the variables in the table.
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Main Analyses
The 30-day readmission rate for the total sample was 26% (31 patients). As
shown in Table 2, there was a marginally lower early readmission prevalence in the
consultation (20%) than TAU condition (32%; χ2 = 2.13, p = .077, NNT = 9).
The rate for the presence of any unplanned return hospital visit within 30 days
(including inpatient readmissions, emergency department visits, and observation status)
was 39% (47 patients). The occurrence of any early hospital return visit was significantly
lower in the consultation (32%) than TAU condition (47%; χ2 = 2.83, p = .046, NNT =
7). More specifically, there were 9 more patients with inpatient readmissions in the
control condition than in the family consultation condition (27 vs. 14) and 4 more
patients with an ED visit (13 vs. 9). There were 3 patients with only observation visits in
each group.
For three patients in the treatment group, the intervention could not be completed
because we failed to contact a support person for the patient; two of those three were
readmitted within 1 month. Excluding these three patients for the per protocol analyses
slightly enhanced the condition effects noted above. As shown in Table 3, when those
three patients were removed from the analyses, the readmission rate was significantly
lower in the treatment group (18%) than in the control group (32%; p = .039; NNT = 7).
Next, readmission rates were lower in the treatment group (28% vs. 47%) when
observation and emergency department visits were added into the equation (p = .019;
NNT = 6).
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Table 2. Main Effect of Condition Assignment on 30-Day Readmissions and
Hospital Visits: Intent-to-Treat
Total Sample
(n = 120)
Intent
to
Treat
Analyses
30-Day Readmit
30-Day Any Return Visit
Per Protocol Analyses
30-Day Readmit
30-Day Any Return Visit

47 (39%)
73 (61%)
31 (26%)
89 (74%)

Family
Consultation
(n = 60)

TAU Control

12 (20.0%)
19 (31.7%)
(n = 57)
10 (17.5%)
16 (28.1%)

19 (31.7%)
28 (46.7%)
(n = 60)
19 (31.7%)
28 (46.7%)

χ2

p

2.13
2.83

.077
.046

3.13
4.31

.039
.019

(n = 60)

The 3-month readmission rate for the total sample was 45% (66 patients). As
shown in Table 3, the consultation condition (40%) and the TAU condition (50%; χ2 =
1.21, p = .141) did not statistically differ on readmission rates. The rate for the presence
of any unplanned return visit within 3 months was 61%. For this outcome variable,
readmission rates were marginally lower in the consultation condition (55%) and the
TAU control (67%; χ2 = 1.71, p = .075).
Table 3. Main Effect of Condition Assignment on Readmissions and Hospital
Visits at Three Months
Total Sample
(n = 120)
Intent to Treat Analyses
3 Month Readmit
3 Month Any Return Visit

54 (45%)
73 (61%)

Family
Consultation
(n = 60)
24 (40%)
33 (55%)

TAU Control χ2

p

(n = 60)
30 (50%)
40 (67%)

.141
.075

1.21
1.71

One month follow up: Self-Report Measures
We retained 84 patients (70%) for 1-month follow up measures of social support,
adherence, depression, and anxiety. The remaining patients were unable to be reached by
phone, and did not respond by mail. First, completers (n = 84) and non-completers (n =
36) were compared across all baseline variables. The only significant difference between
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groups was that completers were younger than non-completers (t = 2.06, p = .041). Of the
completers, 43 were from the consultation condition, and 41 were from the control group;
non-completion was unrelated to experimental condition.
As shown in Table 4, there was no difference in change in social support,
adherence, depression, or anxiety between conditions. Furthermore, social support,
adherence, depression, and anxiety were meant to be examined as potential mediators of
the intervention but were ruled out because the change in these variables at one month
was not correlated with the main outcomes.
Table 4. Change in Self-Report Measures Between Groups at One Month Follow-up
Total
n = 84
Social Support
Baseline M (SD)
Social Support
1 month M (SD)
Social Support
Change M (SD)
Adherence
Baseline M (SD)
Adherence
1 month M (SD)
Adherence
Change M (SD)
Depression
Baseline M (SD)
Depression
1
month M (SD)
Depression
Change M (SD)
Anxiety
Baseline M (SD)
Anxiety
1 month M (SD)
Anxiety
Change M (SD)

2.83 (1.08)

Family
Consult
n = 43
2.87 (0.99)

Control
Group
n = 41
2.79(1.17)

2.94 (0.95)

3.02 (0.90)

2.85 (1.01)

0.11 (1.04)

0.16 (0.75)

0.06 (1.28)

2.41 (0.59)

2.36 (0.57)

2.45 (0.63)

2.54 (0.50)

2.49 (0.45)

2.60 (0.54)

0.14 (0.52)

0.13 (0.53)

0.14 (0.51)

6.73 (4.67)

7.03 (4.38)

6.41 (5.00)

5.60 (4.69)

6.56 (4.90)

4.59 (4.23)

-1.14 (4.09)

-0.48 (4.29)

-1.82 (3.79)

4.99 (4.52)

5.04 (4.35)

4.93 (4.75)

4.41 (5.05)

4.81 (5.30)

4.00 (4.81)

-0.58 (4.04)

-0.24 (3.77)

-0.93 (4.32)

F

p

0.19

.662

0.01

.921

2.32

.132

0.60

.441
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Other variables that predicted readmissions
Comorbidities
As shown in Table 5, history of delirium (χ2 = 11.29, p = .001) and history of
positive head imaging (χ2 = 6.78, p = .009) were both cognitive risk factors that
significantly predicted early readmissions.
Baseline Variables
As shown in Table 5, there was a trend such that women were marginally more atrisk for an early readmission than men (p = .061). The MoCA was the only baseline
measure that predicted readmissions (p = .015). Baseline social support, adherence,
depression, anxiety, and health literacy did not predict readmissions across groups.
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Table 5. Relationship of Baseline Variables with Presence of 30-Day Readmission
Variable

Total
N = 120

Readmit
n = 31 (25.8%)

No Readmit
n = 89 (74.2%)

t or χ2

Demographics
Age (M, SD)
57.5 (14.4)
60.32 (14.8)
56.5 (14.2)
-1.27
Gender (Male)
60 (50%)
11 (35.5%)
49 (55.1%)
3.52†
Gender (Female)
60 (50%)
20 (64.5%)
40 (44.9%)
3.52†
Race = Black
103 (85.8%)
29 (93.5%)
74 (83.1%)
2.21
Race = White
15 (12.5%)
2 (6.5%)
15 (16.9%)
Grade > 12th
51 (42.5%)
15 (48.4%)
36 (40.4%)
0.59
Medical risk factors
CHF
58 (48.3%)
18 (48.4%)
40 (44.9%)
1.59
Smoking
71 (59.2%)
16 (51.6%)
55 (61.8%)
0.99
Diabetes
74 (61.7%)
19 (61.2%)
55 (61.8%)
0.00
Hypertension
118 (98.3%)
29 (93.5%)
89 (100.0%)
N/A
COPD
22 (18.3%)
5 (16.1%)
17 (19.1%)
0.14
Blood Urea Nitrogen
40.72 (22.65) 36.68 (20.87)
42.12 (23.19)
1.15
Serum Creatinine
7.35 (3.65)
6.84 (3.72)
7.53 (3.62)
0.92
Phosphorous
4.37 (1.69)
4.27 (1.92)
4.41 (1.62)
0.38
Charlson Index
7.47 (3.14)
8.32 (2.98)
7.17 (3.15)
1.78
Behavioral risk factors
Psychiatric diagnosis
35 (29.2%)
9 (29.0%)
26 (29.2%)
0.00
Psychiatric medication 30 (25.0%)
6 (19.4%)
24 (27.0%)
0.71
Substance use history
31 (25.8%)
9 (29.0%)
22 (24.7%)
0.22
Positive tox screen
11 (9.2%)
4 (12.9%)
7 (7.9%)
0.70
Past Year Admissions
2.94 (3.06)
3.94 (4.32)
2.60 (2.42)
-1.64
Cognitive risk factors
Delirium
37 (30.8%)
17 (54.8%)
20 (22.5%)
11.29**
Positive head imaging 61 (50.8%)
22 (71.0%)
39 (43.8%)
6.78**
History of seizures
14 (11.7%)
4 (12.9%)
10 (11.2%)
0.06
History of hypoxia
19 (15.8%)
6 (19.4%)
13 (14.6%)
0.39
Dementia
5 (4.2%)
2 (6.5%)
3 (3.4%)
0.55
Stroke history
10 (8.3%)
4 (12.9%)
6 (6.7%)
1.14
MoCA Total
20.47 (4.50)
18.79 (5.66)
21.06 (3.88)
2.47*
Baseline Assessment
REALM-R
5.22 (2.62)
5.10 (2.92)
5.26 (2.52)
0.27
REALM-SF
5.46 (2.11)
5.24 (2.37)
5.58 (2.01)
0.97
Social Support
2.93 (1.00)
3.01 (0.97)
2.91 (1.02)
-0.47
Adherence
2.38 (0.60)
2.45 (0.59)
2.35 (0.60)
-0.79
Depression
6.78 (4.59)
6.52 (4.10)
6.88 (4.77)
0.38
Anxiety
5.29 (4.56)
4.06 (4.14)
5.58 (4.66)
1.61
Note. † < .10 *p <.05, ** p<.01; N/A – does not meet criteria for Chi Square test
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Therapist Post-Session Ratings
The therapist session ratings were analyzed in an exploratory fashion of predictors
of readmissions within the family meeting condition. Only one item (“seemed to
appreciate the consult”) predicted lower risk of an early readmission (t = 2.26, p = .046).

Moderation Analyses
There was a trend of a moderation that the intervention worked better for patients
with higher baseline MoCA scores, but the effect failed to reach significance (p = .116).
In the consultation condition, readmitted patients had numerically lower cognitive
functioning scores (M = 16.8, SD = 6.6) than patients who were not readmitted (M =
21.4, SD = 3.8), whereas, in the control group, cognitive functioning scores were similar
for patients who were (M = 20.0, SD = 4.7) and were not (M = 20.6, SD = 4.0)
readmitted. There was also a trend that the intervention worked better for patients with no
history of substance abuse (n = 89), but the effect failed to reach significance (p = .105).
In patients without a history of substance abuse (n = 89), there was a lower readmission
rate in the family consult group (16%) versus the control group (35%; p < .042). In the 31
patients with a history of substance use, the readmission rate was surprisingly
significantly higher (p = .042) in the treatment group (36%) versus the control group
(25%). Gender and method of contact for the intervention (in person versus phone) did
not moderate the efficacy of the intervention.
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CHAPTER 4 DISCUSSION
A brief behavioral intervention—consulting with the patients’ family members
about the patient’s cognitive status and other risk factors and the need for better
medication adherence—reduces early hospital readmissions and all unplanned hospital
visits among patients with ESRD. Many patients with ESRD are at substantial risk for
early readmission, particularly due to cognitive impairment, low health literacy, and
subsequent nonadherence to medications and dialysis. Intervening with family members
in a manner that addresses these deficits reduces the likelihood of early readmission.
The effect size of this family consultation on early readmissions (reducing early
readmissions from 32% to 20%) was clinically significant. The effect size (NNT)
obtained in this study suggests that only 6 or 7 patients need to receive this consultation
to reap the benefits of one patient avoiding an early readmission. We can find no other
study demonstrating a comparable reduction in readmission rates in patients with ESRD.
On a practical level, the brevity and simplicity of the intervention means that an effect
size of the magnitude achieved in this study would be more than enough for the savings
of this intervention would outweigh its costs. In this case, a psychology doctoral student
conducted the initial assessment, which required about 20 minutes to obtain data on
cognitive impairment, health literacy, and social support, and then less than 10 minutes,
on average, to provide the consultation. Including time for note writing and chart review,
the actual billing in most medical settings would be for one hour, with an estimated cost
of $220 for a psychologist in this setting. The average cost per inpatient day in Michigan
is $2132 dollars, with a median length of stay of 4.0 days, and the average cost of an
emergency room visit is $1233 (Kshirsagar, Hogan, Mandelkehr, & Falk, 2000). Thus,
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the total net savings of this intervention are roughly estimated to be at $81,752 for this
sample (n = 60), or an average of over $1200 per patient. Beyond the economics,
however, are the benefits of improving the health outcomes of substantial numbers of
patients.
Notably, this trial has substantial generalizability or external validity in that it
excluded few patients, was conducted with high feasibility—at bedside or via
telephone—and did not rely on special resources or high involvement from other
providers within the nephrology unit. Furthermore, the sample was one that is often
viewed as particularly high risk: urban, largely African American patients, with multiple
social, economic, and behavioral risk factors. Therefore, we believe that this intervention
can readily be implemented on other nephrology units, and perhaps other hospitalized
populations with chronic disease and high risk for readmission.
Additionally, I believe that the impact of the intervention was likely attenuated by
the lack of integration of the psychologist consultant with the rest of the team in the
nephrology unit. Integrated care has been identified as a key predictor of success in
behavioral health interventions; therefore, we expect that a greater reduction in early
readmissions might occur if the psychologist worked more closely with other providers
on the unit, attended interdisciplinary care meetings, and documented behavioral
medicine notes in the EHR (Bridges et al., 2015; Crosson, 2009).
It is disconcerting that this basic assessment and family consultation rarely
happens in hospitals. Many patients and family members in this trial remarked that no
one had ever explained to them that cognitive impairment was common in patients with
ESRD, and that such impairment puts them at risk for missing medications and dialysis
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treatments, resulting in further hospital care. In addition, some patients reported some
mistrust of their providers, which is consistent with the literature on difficult patientprovider relationships in patients with chronic illnesses (Kammerer, Garry, Hartigan,
Carter, & Erlich, 2007). With these concerns in mind, it is imperative that providers listen
to patients’ concerns, assess their risk factors, engage the family in the patient’s health
care, and build trust to increase their motivation to follow through on discharge
recommendations. More research is need to determine how to address this issue, which
could result in substantial improvement in care both in patients with ESRD and in the
national healthcare system in general.
This study was designed with an effectiveness rather than efficacy framework,
and thus did not rely on special conditions, resources, or even above average levels of
cooperation from other providers within the nephrology unit. Therefore, we believe that
this same intervention could easily be implemented on any nephrology unit. We believe
that effectiveness studies are an especially important step in translating research into
clinical practice (Glasgow, Lichtenstein, & Marcus, 2003). There is already an abundance
of trials demonstrating the efficacy of behavioral health interventions in medical
populations such as congestive heart failure and liver disease, but there remains a lack of
implementation (Brownson, Colditz, & Proctor, 2012).
One limitation of this study is that we do not know which social, emotional, or
behavioral changes family members and patients might have made after the consultation
that reduced early readmission rates. Our hypotheses that the family meetings improved
adherence by way of social support compensating for patient cognitive impairment or
poor health literacy was not supported by the 1-month follow up self-report measures.
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The findings (or lack thereof) in the previous paragraph require some explanation.
One possibility is that our assessment measures for social support and adherence may
have had shortcomings in terms of their validity. For social support, it would have been
useful to obtain reports from the family members who participated in the meeting,
because it was their behavior that we were actually intending to change. This also would
have been useful for a manipulation check about the success of the psychoeducation
piece of the meeting. For adherence, we were working with patients with cognitive
impairment and a low education level. Therefore, by definition we know that they are
likely to be poor historians when reporting on their ability to take their medications on
time. More accurate measures of adherence such as electronic pill-boxes or records of
dialysis attendance would have been preferable. Overall, the limitations of these
assessment measures prevented us from drawing meaningful conclusions regarding the
mechanisms of change in this intervention.
Therefore, we suspect that the consultation led the family member or support
person to help patients remember to take their medications, even though the self-reported
adherence and social support scores in this study do not support this. More than half of
the patients with ESRD in the nephrology inpatient population have some cognitive
impairment, so it is not surprising that they have difficulty with medication adherence.
Although willful nonadherence to the treatment regimen may occur for some patients
with ESRD, cognitive deficits remain woefully undetected and unmanaged when
discharge planning, and these impairments appear to be a key factor in early hospital
readmissions (Jasinski et al., in press). Furthermore, most of the patients in this sample,
and many of those with ESRD in general, come from disadvantaged socioeconomic
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backgrounds. We believe that this family consultation raises awareness of barriers to
adherence such as cognitive impairment and low health literacy, and encourages support
people to help patients compensate—and the patient to accept the help—for these
challenges. We believe that this family consultation raises awareness of barriers to
adherence such as cognitive impairment and low health literacy, and allows support
people to help patients compensate for these challenges.
The lack of significant moderating variables suggests that this intervention would
be effective across a wide range of patients. However, there were two trends that merit
comment. It was surprising that patients with less cognitive impairment seemed to benefit
more from the intervention than those with more severe CI. Perhaps instead of this
intervention working by family members compensating for patients who were incapable
of caring for themselves, this intervention works best through family members helping
patients who still have some ability to actively participate in their care and coordinate
ways that their support people can help them adhere to their medication regimen. Second,
although the moderation did not reach significance, it appeared that the intervention may
have worked better in patients with no substance abuse history. This intervention did not
target substance abuse, and therefore the same rate of reduction in readmissions may not
occur with patients who are actively using. It is possible that substance use overrides any
benefits that might be obtained by improved adherence.

Patient-Provider Relationships
These results have implications for the issue of patient-provider relationships.
There has been a robust literature linking better patient-provider relationships with better
treatment adherence. The idea is that when patients trust their providers more, they are
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more likely to follow through on recommendations (Ciechanowski, Katon, Russo, &
Walker, 2001). Although it might seem that trusting one’s provider should be automatic,
our fragmented healthcare system has created situations where providers have little time
to actually speak to patients (Nam, Chesla, Stotts, Kroon, & Janson, 2011). This has led
to many patients having a great deal of frustration, as the healthcare system often does
not meet their expectations (Naidu, 2009).
There are several reasons why patient-provider relationships for patients with
ESRD are particularly at-risk for being troublesome. First, research has shown a negative
correlation between the complexity of the condition that a patient has and their
relationship with their physician (Porcerelli, Murdoch, Morris, & Fowler, 2014). Patients
with ESRD are often the most complex cases within the health care system; therefore, it
is not surprising that the problem is so glaring in this population. Second, there is a
stigma about having ESRD, given that the disease usually results from long-term
unmanaged diabetes and hypertension or substance abuse (Hopper, 1981). Therefore,
there is a belief that these patients are responsible for their declining health, and they are
often reported as being “difficult” to work with. Third, patients with ESRD are
disproportionately represented by low SES African Americans, whereas their physicians
are more likely to be high SES people of European, Middle Eastern, or Asian descent
(Smedley, Stith, & Nelson, 2003). Sometimes, these significant differences in
demographics can breed mistrust on the side of the patient.
Although the problems with patient-provider relationships may sound grim, the
identification of this problem represents an opportunity for improved care. In fact, it is
possible that one of the mechanisms of success of this intervention was through
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increasing the trust of patients and their support people support people in the treatment
team. As part of the protocol, the researcher spoke to the patients and listened to their
concerns, which unfortunately is not something that these patients always encounter.
Therefore, it may be that the improved trust might motivate patients to adhere to their
treatment plans. Future research should consider the patient-provider alliance as a
mediator for this type of intervention.

Iatrogenic Effects of Medicine
Another important reason for decreasing hospital utilization is that there are often
iatrogenic effects of hospital stays. For example, there are many infections, such as C.
Difficile that are common in hospitals, but patients would rarely be exposed to in their
daily lives (Hidron et al., 2008). Additionally, the rate of mistakes by healthcare
providers is higher than most people would expect (Naveh, Katz-Navon, & Stern, 2005).
In our country, there is a misconception that hospitals are places of healing, when in
reality patients are much safer at home, and hospitals should only be used when totally
necessary (Lafont, Gérard, Voisin, Pahor, & Vellas, 2011). Yet, the effect of the
intervention implies a fundamental lack of attention to discharge planning that would
seem to be common sense to most people. With the results of this study exposing these
simple flaws in our healthcare system, there will be a greater understanding in public
perception regarding the risks of hospitalization.

Socio-Economic Status
Socio-economic status is an issue that factors into the health behaviors of patients
with ESRD. This sample of this study would not be appropriate for testing the
moderating effects of SES, given that the same was relatively homogenous with mostly
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low-income, inner-city African Americans. However, the results demonstrate that an
intervention based on psychoeducation can be effective within this population. These
patients generally had below average health literacy, and the fact that the intervention
was able to work in spite of this is promising. It will be important to continue to develop
and test interventions that work with low SES populations, in order to reduce the health
disparities nationwide (Goldman & Smith, 2002).

Cognitive Impairment as a Predictor of Readmissions
Hypotheses were confirmed that three indicators of cognitive impairment were
predictive of early readmissions: delirium, positive head imaging, and low scores on the
Montreal Cognitive Assessment. No other biological/medical risk factors (such as serum
creatinine or BUN) predicted early readmissions. There were fewer baseline predictors of
readmissions than we expected, although it is possible that the effect of the intervention
might have diluted some of these effects. Although this type of study is novel within the
kidney disease population, the findings are consistent with a growing cardiology
literature showing that cognitive impairment is one of the key factors in early hospital
readmissions, but is often ignored in medical settings (Cameron et al., 2010; Dodson et
al., 2013; Huijts et al., 2013; Ketterer, Draus, et al., 2014; McLennan, Pearson, Cameron,
& Stewart, 2006; O'Donnell et al., 2012). Finally, in addition to confirming that cognitive
impairment predicts early readmissions, the results demonstrated that it is possible to
identify patients who are at risk and intervene in a way that compensates for cognitive
deficits to actually prevent readmissions.
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Limitations
First, our outcome measure did not account for readmissions or hospital visits to
external health care systems. This means that there might be some missing readmissions
in our tally, which would skew our main outcome data, and not be consistent with the
method that CMS uses for calculating readmission penalties. However, through phone
conversations with patients at follow up, we have reason to believe that such external
readmissions were rare, and that they would be randomly distributed across experimental
conditions even if they did occur.
Second, only one psychologist was used to conduct the family meetings. The
literature has shown that the individual ability of therapists can have a major impact on
outcomes, but we did not have other consultants available (Crits-Christoph & Mintz,
1991). Therefore, it is possible that other psychologists might have different levels of
success with this intervention. Yet, the therapist’s level of training (master’s degree) and
supervision in this study are roughly consistent with what might be expected from
providers administering this intervention in real world settings. Therefore, generalization
to other consultants would need to be demonstrated in replication studies.
Next, specific reasons for readmission are complex and not well delineated in
medical records. These patients are generally very ill, and linking the intervention to
changes in adherence or family relations, and subsequently to health changes needs
further study. Finally, it is likely that this intervention is most effective with subsets of
patients, such as those with a certain degree of cognitive impairment or certain types of
family relations, but our sample was not large enough to reliably test such moderators.
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In terms of the implementation of the intervention, we were limited by the
inability to contact support people for three patients. However, this likely reflects the
reality of clinical practice; overall, we were pleased with the overall rate of contact with
support people. Similarly, we would have preferred to have conducted more of the
interventions face-to-face. Again, it was important to prioritize completing the
intervention over its location, so conducting a portion of them over the phone was
expected. However, it is possible that if the intervention were a routine part of the
standard of care, that more could have been conducted at bedside.

Conclusions
The results of this study represent the potential for a “win-win” scenario; an
intervention that improves patient care while reducing health care expenditures.
Therefore, there is a compelling argument for rapidly moving forward to promote and
disseminate such interventions of this nature. The next objective would be to run a
replication study with a methodology that addresses the aforementioned limitations and
greater integration with the rest of the health care team. From a long-term perspective,
these results support greater involvement of behavioral medicine in treatment planning.
This intervention was carried out by a graduate student in clinical psychology, who was
supervised by a senior clinical health psychologist. Therefore, we believe that this
intervention could be implemented by mid-level providers such as physician assistants,
nurses, and social workers, who are trained and supervised by a health psychologist.
Additionally, episodic, longer term follow-up may be necessary in order to maintain the
benefits of the intervention. We also think that this same type of family meeting will be
successful with other populations of inpatients with chronic diseases where cognitive
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impairment is common, such as congestive heart failure or liver disease. As our national
health care system shifts from a fee-for-service based model to one that is focused on
value, interventions such as this one will become increasingly vital.
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APPENDIX A. STUDY DETAILS
FAMILY CONSULT PROTOCOL
1) Introductions:
a. Introduce self and obtain names of support people present and their
relationship to the patient.
b. Make efforts to establish rapport and trust.
2) Rationale
a. Friends and family can make a major difference for patients with ESRD in
terms of health and quality of life.
b. Non-threatening language such as “improving stress and coping” to cite
rationale for study
c. Patients on dialysis have a high rate of being in and out of the hospital
over and over. The goal is to keep you healthy and out of the hospital.
3) History
a. Review patient/family understanding of events that caused the hospital
admission
b. Empathize with frustration about the burden that their care requires (costs,
travel, side effects, insurance, etc.)
c. To patient: Many patients on dialysis say that they feel burdened by all of
the things they need to do to take care of their health. Do you ever feel
that way?
d. To support: How aware are you of the effort [patient] puts in to manage
the ESRD condition?
e. Assess how involved the support people currently are in terms of
managing ESRD
4) Medications
a. Have patient do clock draw so support people can observe (Goal is to
make support people aware of the severity of cognitive impairment)
b. Discuss practicality of support people helping with medication adherence.
c. Recommend use of pillbox, and assess how patient refills medications.
5) Cognitive Impairment
a. Explain how risk of “forgetfulness” or “confusion” increases with renal
failure.
b. “Blame the illness or medications” for these symptoms, in order to avoid
stigmatization
c. Assess subjective experience of cognitive impairment, from patient and
support people perspective.
d. Discuss findings from baseline cognitive screening.
e. Explain the cognitive symptoms, and how family/friends might notice it
before the patient.
6) Wrap Up
a. Offer to answer any other questions.
b. Help direct patient and family member to appropriate member of medical
staff if I cannot answer the question.
c. Ask participants to reflect on the meeting
7) As needed: Motivational Interviewing Techniques
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a. Throughout the meeting, be mindful of stage of change for both patients
and support people in terms of health behaviors (especially medications)
b. Roll with patients/families who display resistance, and/or those in the precontemplative stage of change
c. Pros and Cons technique
d. Explore barriers to social support collaboration to medication adherence
and communication with patient.
e. Remind participants that the decision is theirs
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CONSENT FORM
Mark W. Ketterer, PhD
Henry Ford Hospital/A2
2799 West Grand Boulevard
Detroit, MI 48202
1. WHY IS THIS RESEARCH BEING DONE?
To make reading this consent form easier, the word “you” refers to you throughout the
consent form.
You have been asked to take part in a research study because you have spent time as an
inpatient in the Nephrology unit at Henry Ford Hospital. The purpose of this research study
is to determine how talking about your health care with a family member or friend influences
your health.
There will be approximately 150 people in this research study at Henry Ford Health
System (HFHS).
2. WHAT WILL HAPPEN IF I TAKE PART IN THIS RESEARCH STUDY?
There will be two groups in the study. The group you are assigned to will be chosen by chance
(like flipping a coin).
Your participation in this study will last up to one month after your discharge from the hospital.
As part of this study, you will have no additional visits to the clinic, but will be visited by our
research staff once or twice during your hospital stay, and once after your discharge.
At visit 1, you will have the following procedures:
Extra and not experimental:
• Your records will be reviewed for events that might affect your cognitive status, and your
family member may be asked if we may proceed with following you for the study.
• You will be asked to complete a series of simple cognitive task in questionnaire form
• We estimate the time commitment for you at 20 minutes.
At visit 2, you will have the following procedures:
Extra and experimental:
• Within a few days of visit 1, and before you are discharged, we may have a discussion
with you and one or more of your family members or friends about how to take care of
your chronic illness at home.
• We estimate the time commitment for you and your family member at 45 minutes.
• This visit applies to only 1 of the 2 randomly assigned groups in the study.
At visit 3, you will have the following procedures:
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Extra and experimental: One month after your discharge from the hospital, we will contact
you or your family member by phone to ask a few questions about the self-management of
your chronic illness. We estimate the time commitment for you and your family member at 15
minutes.
3. WHAT ARE THE RISKS OF THE STUDY?
You should tell the person obtaining your consent about any other medical research
studies you are
involved in right now.
It is not expected that you will have any complications or discomforts from being in this
study. There
may be risks or discomforts that are not known at this time.
4. WHAT ARE THE BENEFITS TO TAKING PART IN THE STUDY?
The benefits of participating in this study may include: helping you with self-management
of your illness. You may not be helped by participating in this study. However, others may be
helped by what is learned from this research.
5. WHAT OTHER OPTIONS ARE THERE?

You do not have to participate in this study. Your other choices may include:
•

•
•

Getting treatment or care for kidney disease without being in a study, such as the routine
care in the Nephrology unit that does not involve meetings with family members or
friends.
Taking part in another study
Getting no treatment

Talk to your doctor about your choices before you decide if you will take part in this
study.
6. WHAT ABOUT CONFIDENTIALITY?
By signing this consent form, you agree that we may collect, use and release your personal
and health information for the purpose of this research study.
We may collect and use:
•
Your existing medical records.
•
New health information created during this study.
•
Health insurance and other billing information.
We may release this information to the following people:
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•
•
•
•

The Principal Investigator and his/her associates who work on, or oversee the
research activities.
Government officials who oversee research (Food and Drug Administration).
Your insurance company or others responsible for paying your medical bills.
Other researchers at other institutions participating in the research.

Once your information has been released according to this consent form, it could be released
again and may no longer be protected by federal privacy regulations.
This consent form, test results, medical reports and other information about you from this
study may be placed into your medical record. Generally, you are allowed to look at your
medical record. During the research study, you will be allowed to look at your research study
information that is not in your medical record.
HFHS or others may publish the results of this study. No names, identifying pictures or other direct identifiers will be used
in any public presentation or publication about this study unless you sign a separate consent allowing that use.

This consent to use and release your personal and health information will expire at the end of this research study.

You do not have to sign this consent to release your medical information and may cancel it at
any time. If you decide not to sign this consent or cancel your consent, you cannot participate
in this study. If you notify us that you wish to stop participating in this study, we may
continue to use and release the information that has already been collected. To cancel your
consent, send a written and dated notice to the principal investigator at the address listed on
the first page of this form.
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as
required by U.S. Law. This web site will not include information that can identify you. At
most, the Web site will include a summary of the results. You can search this Web site at any
time.
7. WHAT IF I AM INJURED?
There is no federal, state, or other program that will compensate you or pay for your
medical care if you are injured as a result of participating in this study. You and/or your
medical insurance may have to pay for your medical care if you are injured as a result of
participating in this study. You are not giving up any of your legal rights by signing this
consent form.
8. WHO DO I CALL WITH QUESTIONS ABOUT THE STUDY OR TO REPORT
AN INJURY?
Mark W. Ketterer, or his staff member has explained this research study and has offered to
answer any questions. If you have questions about the study procedures, or to report an
injury you may contact Dr. Ketterer at (734-642-8776). Medical treatment is available to you
in case of an injury.
If you have questions about your rights as a research subject you may contact the Henry Ford
Health System IRB Coordinator at (313) 916-2024. The IRB is a group of people who review
the research to protect your rights.
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9. DO I HAVE TO PARTICIPATE IN THIS STUDY?
No, your participation in this research study is voluntary. If you decide to participate, you
can stop at any time. If this happens, you may be asked to return for a visit for safety reasons.
You will get the same medical care from HFHS whether or not you participate in this study.
There will be no penalties or loss of benefits to which you would otherwise be entitled if you
choose not to participate or if you choose to stop your participation once you have started.
You will be told about any significant information that is discovered that could reasonably
affect your willingness to continue being in the study.
10. WHO ELSE CAN STOP MY PARTICIPATION?
The Principal Investigator, sponsor or your doctor can end your participation in the research
study at any time. If this happens, you may be asked to return for a visit for safety reasons.
11. WILL IT COST ANYTHING TO PARTICIPATE?
We do not expect there to be any additional costs to you if you participate in this study.
Items related to the routine medical care that you would receive even if you did not
participate in this study will be billed to you or your insurance company. You have the right
to ask what it will cost you to take part in this study.
12. WILL I BE PAID TO PARTICIPATE?
You will be paid $20 after completing the first set of questionnaires, and $20 after
completing the follow-up phone call. If you complete the study, you will be paid a total of
$40. If you do not finish the study, you will be paid for the part that you did complete.
13. CONSENT
You have read this consent form or it has been read to you. You understand what you are
being asked to do. Your questions have been answered. Any technical terms you did not
understand have been explained to you. You agree to be in this study. You will be given a
copy of this consent form.
__________________________________________
Signature of Subject

_______________
Date
Time

__________________________________________
Print Name of Subject
__________________________________________
Witness to Signature

_______________
Date

Time

_______________
Date

Time

__________________________________________
Print Name of Person Obtaining Consent
__________________________________________
Signature of Person Obtaining Consent
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__________________________________________
Signature of Person Signing For Subject

_______________
Date
Time

__________________________________________
Print Name of Person Signing for Subject and Relationship to Subject*
__________________________________________
Print Name of Subject
__________________________________________
Witness to Signature

_______________
Date

Time

__________________________________________
Signature of Person Obtaining Consent

_______________
Date

Time
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APPENDIX B. MEASURES
MONTREAL COGNITIVE ASSESSMENT
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REALM

REALM-R Examiner Record
Reading
Level

Patient Name/
Subject # ____________________________________________ Date of Birth __________________

_____________

Grade
Completed _____________

Date ________________ Clinic _________________________________ Examiner _______________________________________

fat

fatigue

____

flu

directed

____

pill

colitis

____

allergic

____

constipation

____

jaundice

____

osteoporosis

____

anemia

____

Fat, Flu, and Pill are not scored. We have previously
used a score of 6 or less to identify patients at risk for
poor literacy.

Score ______
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REALM-SF Form
Patient name ___________________ Date of birth__________________ Reading level________

Date ________________ Examiner ______________________ Grade completed ___________

Menopause
Antibiotics
Exercise
Jaundice
Rectal
Anemia
Behavior

Instructions for Administering the REALM-SF
1.

Give the patient a laminated copy of the REALM-SF form and score answers on an unlaminated
copy that is attached to a clipboard. Hold the clipboard at an angle so that the patient is not
distracted by your scoring. Say:
"I want to hear you read as many words as you can from this list. Begin with
the first word and read aloud. When you come to a word you cannot read, do
the best you can or say, 'blank' and go on to the next word."

2.

If the patient takes more than 5 seconds on a word, say "blank" and point to the next
word, if necessary, to move the patient along. If the patient begins to miss every word,
have him or her pronounce only known words.
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MSSS-5

1. How often is someone available to take you to the doctor if you need
to go?
_____ None of the time
_____ A little of the time
_____ Some of the time
_____ Most of the time
_____ All of the time
2. How often does someone help you take your medications?
_____ None of the time
_____ A little of the time
_____ Some of the time
_____ Most of the time
_____ All of the time
3. How often is someone available to listen to concerns or worries about
your medical care?
_____ None of the time
_____ A little of the time
_____ Some of the time
_____ Most of the time
_____ All of the time
4. How often does someone help you manage your medical problems?
_____ None of the time
_____ A little of the time
_____ Some of the time
_____ Most of the time
_____ All of the time
5. How often does someone encourage you to eat the right foods?
_____ None of the time
_____ A little of the time
_____ Some of the time
_____ Most of the time
_____ All of the time

58
ITAS-M

1. In the last month, how often did you forget to take your medications?
_____ 0% of the time
_____ 1-20% of the time
_____ 21-50% of the time
_____ More than 50% of the time
2. In the last month, how often were you careless about taking your
medications?
_____ 0% of the time
_____ 1-20% of the time
_____ 21-50% of the time
_____ More than 50% of the time
3. In the last month, how often did you stop taking your medications
because you felt worse?
_____ 0% of the time
_____ 1-20% of the time
_____ 21-50% of the time
_____ More than 50% of the time
4. In the last month, how often did you miss taking your medications for
any reason?
_____ 0% of the time
_____ 1-20% of the time
_____ 21-50% of the time
_____ More than 50% of the time
5. In the last month, how often did you miss your planned dialysis
sessions for any reason?
_____ 0% of the time
_____ 1-20% of the time
_____ 21-50% of the time
_____ More than 50% of the time
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PATIENT HEALTH QUESTIONNAIRE - 8

Personal Health Questionnaire Depression Scale (PHQ-8)
Over the last 2 weeks, how often have you been bothered by any of the following problems?
(circle one number on each line)
Several
days

More than
half
the days

Nearly
every day

1. Little interest or pleasure in
doing things ...................................................... 0

1

2

3

2. Feeling down, depressed, or hopeless .............. 0

1

2

3

3. Trouble falling or staying asleep, or
sleeping too much ............................................. 0

1

2

3

4. Feeling tired or having little energy.................... 0

1

2

3

5. Poor appetite or overeating ............................... 0

1

2

3

6. Feeling bad about yourself, or that you
are a failure, or have let yourself or
your family down ............................................... 0

1

2

3

7. Trouble concentrating on things, such as
reading the newspaper or watching
television ........................................................... 0

1

2

3

8. Moving or speaking so slowly that other
people could have noticed. Or the opposite –
being so fidgety or restless that you have
been moving around a lot more than usual ....... 0

1

2

3

How often during the past 2
weeks were you bothered by...

Not
at all

Scoring
If two consecutive numbers are circled, score the higher (more distress) number. If the numbers are not
consecutive, do not score the item. Score is the sum of the 8 items. If more than 1 item missing, set the
value of the scale to missing. A score of 10 or greater is considered major depression, 20 or more is
severe major depression.
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GAD-7

Generalized Anxiety Disorder 7-item (GAD-7) scale
Over the last 2 weeks, how often have you been
bothered by the following problems?

Not at
all sure

Several
days

Over half
the days

Nearly
every day

1. Feeling nervous, anxious, or on edge

0

1

2

3

2. Not being able to stop or control worrying

0

1

2

3

3. Worrying too much about different things

0

1

2

3

4. Trouble relaxing

0

1

2

3

5. Being so restless that it's hard to sit still

0

1

2

3

6. Becoming easily annoyed or irritable

0

1

2

3

7. Feeling afraid as if something awful might
happen

0

1

2

3

Add the score for each column

+

+

+

Total Score (add your column scores) =
If you checked off any problems, how difficult have these made it for you to do your work, take
care of things at home, or get along with other people?
Not difficult at all __________
Somewhat difficult _________
Very difficult _____________
Extremely difficult _________

Source: Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing generalized anxiety
disorder. Arch Inern Med. 2006;166:1092-1097.
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Stress and Health Interview
Psychologist Post-Treatment Rating Form
Patient ID:

Psychologist:

Date of session:

Start time:

Location:

Support Present:

Duration of session (minutes):

Overall Ratings:
(0 = not at all

1 = a little

2 = moderately 3 = quite a bit

4 = a lot)

___ baseline involvement of support
___ was interested or motivated to participate
___ learned the material being taught
___ was focused on and attentive to the session content (rather than tangential or distracted)
___ participant / psychologist interactions were positive
___ developed greater awareness of barriers to adherence
___ seemed to appreciate the consult
___ Lives with someone (1 = yes, 0 = no)
Session Content Checklist:
___ Provided rationale
___ Included reasons why it will benefit the support people for them to help
___ Reviewed patient/family understanding of events that caused the hospital admission
___ Empathized with frustration of managing chronic illness
___ Showed clock draw
___ Practical issues of support people involvement
___ Pillbox and medication adherence
___ Explained how “forgetfulness” can occur with renal failure and medications
___ Anxiety and/or depression
___ Substance Abuse

Additional Comments:
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
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Background: The U.S. Centers for Medicare and Medicaid Services have mandated
reducing early hospital readmissions (i.e., within 30 days of discharge) to both improve
patient care and reduce expenses. Patients with end-stage renal disease (ESRD) have
relatively high early readmission rates, due in part to their complex medical regimens but
also cognitive impairment, health literacy problems, and lack of social support. We
developed a brief family consultation intervention to address these problems and tested
its ability to reduce early readmissions among patients with ESRD.
Method: 120 hospitalized adults with ESRD (M age = 57.5 years; 50% male; 86%
Black, 12% White) were recruited from an urban, inpatient nephrology unit. Patients
were randomized to family consultation (FC; n = 60) or treatment-as-usual (TAU) control
(n = 60) conditions. Family consultations, conducted either bedside or via telephone,
were conducted with 57 of the 60 assigned patients and covered psychoeducation about
cognitive and behavioral risk factors for readmission and how to compensate for them.
Blinded medical record review was conducted later to determine readmissions within 30
days.
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Results: Chi-square tests and logistic regressions tested intervention effects. Per protocol
analyses (excluding three FC patients who received no consultation) indicated that FC
reduced early readmission (18%) after discharge, compared to TAU (32%; χ = 3.13, p =
.039), and reduced any early hospital return visit (emergency department, brief
observation, or readmission) compared to TAU (28% vs. 47%; χ = 4.31, p = .019). Intentto-treat analyses revealed that FC marginally reduced readmission (20%) compared to
TAU (32%; χ = 2.13, p = .077), but FC still significantly reduced any hospital visit (32%)
compared to TAU (47%; χ = 2.83, p = .046).
Discussion: A brief psychosocial intervention with family members can decrease
readmissions in patients with ESRD, thereby improving health outcomes and reducing
costs.
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